What We're Reading: Page 2
Industry reads hand-picked by our editors
Nov 29, 2023
-
Bloomberg
Bayer M&A Simulation Game Casts Doubt on Any Quick Fixes
-
San Francisco Business Times
Personalized approach to Alzheimer’s Disease draws documentary, criticism
-
ApexOnco
Argenx’s efforts to Advance fall flat
Nov 28, 2023
-
LifeSciVC
Darkest Before Dawn: A Story Of Biotech Optimism In A Tough Market
-
Reuters
Lilly’s Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds
-
Axios
Biden looks to boost domestic drug manufacturing amid shortages
-
USA Today
Medical treatment designed for one patient may be the future for many
Nov 27, 2023
-
Stat
As biotech industry slumps, bioscience job market is upside down
-
Axios
The big question about obesity drugs: Can people ever stop taking them?
-
KFF Health News
Many Autoimmune Disease Patients Struggle With Diagnosis, Costs, Inattentive Care
-
Fierce Biotech
CRISPR Therapeutics laid off staff a week after positive adcomm
Nov 22, 2023
-
Fierce Pharma
CEOs of J&J, Merck, BMS called to testify on drug prices
-
Bloomberg
A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs
-
Stat
Prominent pharmaceutical industry ally Anna Eshoo to retire
-
The Wall Street Journal
Senators Call for Investigation of Health Insurers’ Role in Driving Up Drug Costs
Nov 21, 2023
-
Reuters
Researchers return to Alzheimer’s vaccines, buoyed by recent drug success
-
FirstWord Pharma
MorphoSys pins hopes on “totality of data” for pelabresib in myelofibrosis
-
The Wall Street Journal
Foot Locker, Teamsters Show Their Drug-Benefit Managers the Door
-
Science
As scientists face a flood of papers, AI developers aim to help
Nov 20, 2023
Nov 17, 2023
-
Investor’s Business Daily
Biotech Stocks: The Race For An Alzheimer’s Cure Takes Off
-
ScienceNews
Why a popular breast cancer drug may be less effective for some Africans
-
Reuters
Manufacturer Lonza says it will not fill obesity drug syringes
Previous
